Elanco Animal Health Incorporated (ELAN) shares soared 7.6% in the last trading session to close at $25.18. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.9% loss over the past four weeks.
The sharp rise in ELAN shares can be attributed to the company’s strong fourth-quarter performance and encouraging forward outlook, which reinforced confidence in its ongoing turnaround. Elanco reported a modest earnings beat alongside solid revenue growth, reflecting improving operational execution and steady demand across its core segments. More importantly, management issued constructive 2026 guidance, calling for continued revenue growth and stronger EBITDA expansion supported by margin improvement initiatives and cost efficiencies. This update signaled a clearer path to sustained profitability, strengthening investor sentiment around Elanco’s long-term growth trajectory.
This company is expected to post quarterly earnings of $0.35 per share in its upcoming report, which represents a year-over-year change of -5.4%. Revenues are expected to be $1.28 billion, up 7.7% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Elanco Animal Health, the consensus EPS estimate for the quarter has been revised 1.8% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on ELAN going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Elanco Animal Health is part of the Zacks Medical - Outpatient and Home Healthcare industry. Quest Diagnostics (DGX), another stock in the same industry, closed the last trading session 0.2% lower at $198.61. DGX has returned -3.8% in the past month.
Quest Diagnostics' consensus EPS estimate for the upcoming report has changed +0.3% over the past month to $2.39. Compared to the company's year-ago EPS, this represents a change of +8.1%. Quest Diagnostics currently boasts a Zacks Rank of #3 (Hold).
Free Report: Profiting from the 2nd Wave of AI Explosion
The next phase of the AI explosion is poised to create significant wealth for investors, especially those who get in early. It will add literally trillion of dollars to the economy and revolutionize nearly every part of our lives.
Investors who bought shares like Nvidia at the right time have had a shot at huge gains.
But the rocket ride in the "first wave" of AI stocks may soon come to an end. The sharp upward trajectory of these stocks will begin to level off, leaving exponential growth to a new wave of cutting-edge companies.
Zacks' AI Boom 2.0: The Second Wave report reveals 4 under-the-radar companies that may soon be shining stars of AI’s next leap forward.
Access AI Boom 2.0 now, absolutely free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Elanco Animal Health Incorporated (ELAN): Free Stock Analysis Report
Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).